Premium
Reversal of iron‐induced dilated cardiomyopathy during therapy with deferasirox in beta‐thalassemia
Author(s) -
Trad Omar,
Hamdan Mohamed A.,
Jamil Altaf,
Khanani Muhammad F.,
Ishaqi M. Kashif,
Shamsi Aisha,
Hayek Mohamed
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21795
Subject(s) - deferasirox , medicine , ejection fraction , dilated cardiomyopathy , ventricle , deferoxamine , cardiomyopathy , cardiology , thalassemia , beta thalassemia , deferiprone , heart failure
A 15‐year‐old male with β‐thalassemia major developed dilated cardiomyopathy secondary to iron‐overload ( Z ‐scores of left ventricle (LV) dimensions >3, ejection fraction (EF) 33%). Treatment with deferoxamine was unsuccessful, presumably due to poor compliance. After 15 months of using deferasirox (DFX), LV end‐diastolic dimension normalized ( Z ‐scores <2), and EF improved to 58%. We conclude that treatment with DFX resulted in a reversal of iron‐induced cardiomyopathy. Pediatr Blood Cancer 2009;52:426–428. © 2008 Wiley‐Liss, Inc.